Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are forms of vitamin B3 that the body turns into NAD+. The biochemical effect is proven: oral doses reliably raise blood NAD+. Clinical benefit in humans is not. Meta-analyses of randomised trials find no improvement in blood sugar, insulin, cholesterol, muscle mass or strength, and only a small diastolic blood-pressure signal so far.
2 of 11 results reported a benefit, from 3 published studies.
3 studies, including a review of trials
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultMuscular force production. Influenced by training, protein intake, hormones, and neuromuscular efficiency.
Also known as: NMN, Nicotinamide mononucleotide, NR, Nicotinamide riboside
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for NMN / NR (NAD+ precursors) in strength.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Be the first to share what you noticed with NMN / NR (NAD+ precursors) for strength. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 40275690 2025 | Systematic review | - | - | 5-time chair stand test (5CST) | -0.21 (p = 0.41) | No benefit |
| PMID 40275690 2025 | Systematic review | - | - | Gait speed | -0.01 (p = 0.79) | No benefit |
| PMID 40275690 2025 | Systematic review | - | - | Handgrip strength (left) | 0.61 (p = 0.42) | No benefit |
| PMID 40275690 2025 | Systematic review | - | - | Handgrip strength (right) | 0.45 (p = 0.56) | No benefit |
| PMID 40275690 2025 | Systematic review | - | - | Skeletal muscle index (SMI) | -0.42 (p = 0.14) | No benefit |
| PMID 36443648 2023 | Randomised trial | 14 | 24-week | central retinal thickness | reported qualitatively (P = 0.051) | No benefit |
| PMID 36443648 2023 | Randomised trial | 14 | 24-week | change in grip strength | 1.25 kg (95% confidence interval -2.31 to 4.81) | No benefit |
| PMID 36443648 2023 | Randomised trial | 14 | 24-week | change in walking speed | 0.033 m/s (-0.021 to 0.087) | No benefit |
| PMID 36443648 2023 | Randomised trial | 14 | 24-week | prevalence of frailty | reported qualitatively (P = 0.066) | No benefit |
| PMID 35215405 2022 | Randomised trial | 108 | 12 weeks | 5-times sit-to-stand (5-STS) | d = 0.72 | Benefit |
| PMID 35215405 2022 | Randomised trial | 108 | 12 weeks | drowsiness | d = 0.64 | Benefit |